Skip to main content
PROTIA INC. logo

PROTIA INC. — Investor Relations & Filings

Ticker · 303360 ISIN · KR7303360002 KO Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2022-03-31 Major Shareholding Noti…
Country KR South Korea
Listing KO 303360

About PROTIA INC.

https://www.protia.co.kr/en/main

PROTIA INC. is an in-vitro diagnostics (IVD) company that develops, manufactures, and sells a wide range of diagnostic kits and instruments. The company is particularly known for its flagship product, PROTIA Allergy-Q, a multiplex allergy diagnostic kit for the quantitative determination of allergen-specific IgE. Its portfolio also includes point-of-care testing (POCT) solutions like the ImmuneCheck IgG kit, diagnostic tests for infectious and autoimmune diseases, cancer, and antibiotic susceptibility, as well as the ANITIA line for companion animal allergy testing. In addition to its product offerings, PROTIA provides comprehensive protein analysis services, including LC-MS/MS and characterization analysis, aiming to contribute to early disease prediction and diagnosis through innovative technology.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and the purpose of holding (management influence) for the company ProteomeTech. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회 결과' (Regular General Meeting of Shareholders Results) and details the outcomes of various agenda items voted upon during the meeting, such as financial statement approval, director/auditor compensation limits, and stock option grants. This falls directly under the definition of a Declaration of Voting Results.
2022-03-29 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the exchange that does not fit into more specific categories like DIRS (which is for personal trades) or SHA (which is for general share issuance).
2022-03-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically a sale) by an executive (Lee Jong-tae) of the company ProteomeTech. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2022-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a short regulatory filing titled '감사보고서 제출' (Submission of Audit Report) which provides a summary of the audit opinion and key financial figures for the fiscal year. It is a standard regulatory announcement in Korea (DART system) notifying the market that the audit report has been submitted. Following the 'Menu vs Meal' rule, this is an announcement of the report's submission rather than the full audit report itself, making it a Report Publication Announcement (RPA). FY 2021
2022-03-21 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'ProteomeTech' (주식회사 프로테옴텍) covering the fiscal years 2020 and 2021. It includes the independent auditor's opinion from Samil PricewaterhouseCoopers, the financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes. This is a comprehensive financial audit document, not an announcement or a summary, fitting the 'Audit Report' category. FY 2021
2022-03-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.